The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete ...

Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts. This is an ASCO Meeting Abstract from ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements ...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell ...